IN2014CN02805A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02805A IN2014CN02805A IN2805CHN2014A IN2014CN02805A IN 2014CN02805 A IN2014CN02805 A IN 2014CN02805A IN 2805CHN2014 A IN2805CHN2014 A IN 2805CHN2014A IN 2014CN02805 A IN2014CN02805 A IN 2014CN02805A
- Authority
- IN
- India
- Prior art keywords
- compounds
- medicaments
- variables
- inhibitors
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010080805 Factor XIa Proteins 0.000 abstract 1
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 1
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547301P | 2011-10-14 | 2011-10-14 | |
| PCT/US2012/059932 WO2013056034A1 (fr) | 2011-10-14 | 2012-10-12 | Composés de tétrahydroisoquinoléine substitués en tant qu'inhibiteurs du facteur xia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02805A true IN2014CN02805A (fr) | 2015-07-03 |
Family
ID=47116434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2805CHN2014 IN2014CN02805A (fr) | 2011-10-14 | 2012-10-12 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9079929B2 (fr) |
| EP (1) | EP2766347B1 (fr) |
| JP (1) | JP6033318B2 (fr) |
| CN (1) | CN103987696B (fr) |
| ES (1) | ES2579832T3 (fr) |
| IN (1) | IN2014CN02805A (fr) |
| WO (1) | WO2013056034A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102753555B (zh) | 2010-02-11 | 2018-01-12 | 百时美施贵宝公司 | 作为因子xia抑制剂的大环类 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| EP3309148A1 (fr) | 2011-10-14 | 2018-04-18 | Bristol-Myers Squibb Company | Composés de tétrahydroisiquinoline substitués en tant qu'inhibiteurs du facteur xia |
| EP2899183B1 (fr) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Composés de tétrahydroisiquinoline substitués en tant qu'inhibiteurs du facteur Xia |
| EP2766347B1 (fr) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Composés de tétrahydroisoquinoléine substitués en tant qu'inhibiteurs du facteur xia |
| JP6220786B2 (ja) | 2012-07-19 | 2017-10-25 | 大日本住友製薬株式会社 | １−（シクロアルキルカルボニル）プロリン誘導体 |
| EA028581B1 (ru) | 2012-08-03 | 2017-12-29 | Бристол-Маерс Сквибб Компани | ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa |
| UY34959A (es) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Dihidropiridona p1 como inhibidores del factor xia |
| DK2906551T3 (en) | 2012-10-12 | 2018-05-22 | Bristol Myers Squibb Co | CRYSTALLIC FORMS OF A FACTOR XIA INHIBITOR |
| WO2014059202A1 (fr) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Composés de tétrahydroisoquinoléine substitués par guanidine comme inhibiteurs du facteur xia |
| EP2906541B1 (fr) * | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Composés de tetrahydroisoquinoline substitués par guanidine et amine en tant qu'inhibiteurs de factor xia |
| HUE045111T2 (hu) * | 2013-03-05 | 2019-12-30 | Bayer Cropscience Ag | N-(2-metoxibenzil)-4-[(metilaminokarbonil)amino]benzolszulfonamid inszekticidekkel vagy fungicidekkel képzett kombinációjának alkalmazása növénytermesztés hatásfokának növelésére |
| US9738655B2 (en) | 2013-03-25 | 2017-08-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors |
| WO2015054087A1 (fr) | 2013-10-07 | 2015-04-16 | Merck Sharp & Dohme Corp. | Inhibitors du facteur xia |
| UY40230A (es) | 2014-01-31 | 2023-08-15 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden |
| NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
| WO2015123091A1 (fr) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| EP3104703B1 (fr) | 2014-02-11 | 2020-11-18 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| US10093683B2 (en) | 2014-04-22 | 2018-10-09 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| MX2016016870A (es) | 2014-07-01 | 2017-05-01 | Takeda Pharmaceuticals Co | Compuestos heterociclicos y su uso como inhibidores de receptor huerfano relacionado con retinoide (ror) gamma-t. |
| WO2016015593A1 (fr) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
| US10167280B2 (en) | 2014-09-24 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| WO2016046159A1 (fr) * | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| EP3310777B1 (fr) | 2015-06-19 | 2019-10-09 | Bristol-Myers Squibb Company | Diamides macrocycliques en tant q'inhibiteurs du facteur xia |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| US10676477B2 (en) | 2015-07-29 | 2020-06-09 | Bristol-Myers Squibb Company | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group |
| CN107849026B (zh) | 2015-07-29 | 2021-01-01 | 百时美施贵宝公司 | 携带烷基或环烷基p2′部分的因子xia大环抑制剂 |
| WO2017023992A1 (fr) | 2015-08-05 | 2017-02-09 | Bristol-Myers Squibb Company | Nouveaux inhibiteurs de fxia dérivés de glycine substitués |
| US10214512B2 (en) | 2015-10-29 | 2019-02-26 | Merck Sharp & Dohme Corp. | Factor XIA inhibitors |
| US10344039B2 (en) | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
| WO2017123518A1 (fr) * | 2016-01-11 | 2017-07-20 | The Rockefeller University | Immunomodulateurs d'aminotriazole pour traiter des maladies auto-immunes |
| KR102382188B1 (ko) * | 2016-03-17 | 2022-04-05 | 주식회사 체크메이트테라퓨틱스 | NamPT 억제용 신규 화합물 및 이를 포함하는 조성물 |
| EP3500556B1 (fr) | 2016-08-22 | 2023-08-02 | Merck Sharp & Dohme LLC | Dérivés pyridine-1-oxyde et leur utilisation en tant qu'inhbiteurs du facteur xia |
| PT3486242T (pt) | 2016-08-31 | 2022-01-06 | Jiangsu Hengrui Medicine Co | Derivado de oxopicolinamida, método de preparação para esse fim e utilização farmacêutica do mesmo |
| CN109721539B (zh) * | 2017-10-27 | 2021-07-09 | 天津药物研究院有限公司 | 吡唑酰胺类衍生物及其制备方法和用途 |
| CN109867660A (zh) * | 2017-12-01 | 2019-06-11 | 四川科伦博泰生物医药股份有限公司 | 含季铵离子的四氢异喹啉酰胺化合物及其药物用途 |
| US11541049B2 (en) | 2018-03-28 | 2023-01-03 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Tetrahydroisoquinoline derivatives, preparation process and use thereof |
| EP3976027B1 (fr) * | 2019-05-30 | 2025-11-05 | Merck Sharp & Dohme LLC | Dérivés de quinoléine en tant qu'inhibiteurs d'activation du facteur xi |
| US12492187B2 (en) | 2020-04-01 | 2025-12-09 | Merck Sharp & Dohme Llc | Factor XI activation inhibitors |
| WO2021231191A1 (fr) * | 2020-05-12 | 2021-11-18 | Merck Sharp & Dohme Corp. | Inhibiteurs d'activation du facteur xi |
| EP3978487A1 (fr) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | Dérivés de 2-(3-pyridine-2-yl-4-quinoline-4-yl-pyrazol-1-yl)-acétamide comme inhibiteurs du récepteur du facteur de croissance transformant bêta i/alk5 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
| JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| WO1996034010A2 (fr) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibiteurs de la farnesyle transferase |
| US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU717298B2 (en) | 1996-04-03 | 2000-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| BRPI9909660B8 (pt) | 1998-03-19 | 2021-05-25 | Vertex Pharma | compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos |
| CN1138778C (zh) | 1998-05-26 | 2004-02-18 | 沃尼尔·朗伯公司 | 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途 |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| WO2000040571A1 (fr) | 1999-01-02 | 2000-07-13 | Aventis Pharma Deutschland Gmbh | Nouveaux derives d'acide malonique, procedes de preparation de ces derives, leur utilisation et compositions pharmaceutiques les contenant (inhibition de l'activite du facteur xa) |
| EP1016663A1 (fr) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Dérivés de l'acide malonique, procédé pour leur préparation, leur utilisation comme médicaments et compositions les contenant (inhibiteurs du facteur Xa ) |
| SK14232001A3 (sk) | 1999-04-09 | 2002-06-04 | Basf Aktiengesellschaft | Nízkomolekulové inhibítory komplementárnych proteáz |
| WO2000076970A2 (fr) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Composes |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| EP1125925A1 (fr) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Dérivés amines pour le traitement de l'apoptose |
| WO2001085695A1 (fr) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Co. | Analogues de tetrahydroisoquinoline servant de secretagogues d'hormones de croissance |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| ES2329881T3 (es) | 2001-09-21 | 2009-12-02 | Bristol-Myers Squibb Company | Compuestos que contienen lactama y derivados de los mismos como inhibidores del factor xa. |
| AU2002357692A1 (en) * | 2001-11-09 | 2003-05-26 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| JP2007501844A (ja) * | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| EA200700225A1 (ru) | 2004-07-12 | 2008-02-28 | Айдан Фармасьютикалз, Инк. | Аналоги тетрапептида |
| JP5236293B2 (ja) | 2005-01-13 | 2013-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘｉａ因子阻害剤としての置換ビアリール化合物 |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| ES2622488T3 (es) | 2005-06-17 | 2017-07-06 | Basf Se | Procedimiento de producción de reforzadores del blanqueador |
| WO2007070816A2 (fr) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Derives de thiophene en tant qu'inhibiteurs du facteur xia |
| JP2009519966A (ja) | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な６員ヘテロ環 |
| AR058379A1 (es) | 2005-12-14 | 2008-01-30 | Bristol Myers Squibb Co | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. |
| AU2007288253B2 (en) | 2006-08-23 | 2013-05-02 | Xenon Pharmaceuticals Inc. | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| CN101605779B (zh) | 2006-12-15 | 2013-11-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物 |
| MX2009012847A (es) * | 2007-06-13 | 2009-12-08 | Bristol Myers Squibb Co | Analogos dipeptidicos como inhibidores de factores de coagulacion. |
| CN102026996B (zh) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| US8624040B2 (en) | 2009-06-22 | 2014-01-07 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8513433B2 (en) | 2009-07-02 | 2013-08-20 | Angion Biomedica Corp. | Small molecule inhibitors of PARP activity |
| AR077695A1 (es) | 2009-08-04 | 2011-09-14 | Schering Corp | Derivados de pirimidina como inhibidores del factor ixa |
| CN102753555B (zh) | 2010-02-11 | 2018-01-12 | 百时美施贵宝公司 | 作为因子xia抑制剂的大环类 |
| US9161924B2 (en) | 2011-07-08 | 2015-10-20 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| EP3309148A1 (fr) | 2011-10-14 | 2018-04-18 | Bristol-Myers Squibb Company | Composés de tétrahydroisiquinoline substitués en tant qu'inhibiteurs du facteur xia |
| EP2766347B1 (fr) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Composés de tétrahydroisoquinoléine substitués en tant qu'inhibiteurs du facteur xia |
| EP2899183B1 (fr) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Composés de tétrahydroisiquinoline substitués en tant qu'inhibiteurs du facteur Xia |
| EP2794597B1 (fr) | 2011-12-21 | 2017-11-15 | ONO Pharmaceutical Co., Ltd. | Dérivés de pyridinone et de pyrimidinone comme inhibiteurs du facteur xia |
| WO2013111107A1 (fr) | 2012-01-27 | 2013-08-01 | Novartis Ag | Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la kallicréine plasmatique |
| WO2013111108A1 (fr) | 2012-01-27 | 2013-08-01 | Novartis Ag | Dérivés hétéroarylcarboxamide à 5 chaînons comme inhibiteurs de la kallikréine plasmatique |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| SG10201609322QA (en) | 2012-05-10 | 2017-01-27 | Bayer Pharma AG | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| JP6220786B2 (ja) | 2012-07-19 | 2017-10-25 | 大日本住友製薬株式会社 | １−（シクロアルキルカルボニル）プロリン誘導体 |
| EA028581B1 (ru) | 2012-08-03 | 2017-12-29 | Бристол-Маерс Сквибб Компани | ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa |
| UY34959A (es) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Dihidropiridona p1 como inhibidores del factor xia |
-
2012
- 2012-10-12 EP EP12780357.5A patent/EP2766347B1/fr not_active Not-in-force
- 2012-10-12 ES ES12780357.5T patent/ES2579832T3/es active Active
- 2012-10-12 US US14/350,411 patent/US9079929B2/en active Active
- 2012-10-12 IN IN2805CHN2014 patent/IN2014CN02805A/en unknown
- 2012-10-12 CN CN201280061628.1A patent/CN103987696B/zh not_active Expired - Fee Related
- 2012-10-12 WO PCT/US2012/059932 patent/WO2013056034A1/fr not_active Ceased
- 2012-10-12 JP JP2014535916A patent/JP6033318B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6033318B2 (ja) | 2016-11-30 |
| EP2766347A1 (fr) | 2014-08-20 |
| ES2579832T3 (es) | 2016-08-17 |
| CN103987696A (zh) | 2014-08-13 |
| US20140274960A1 (en) | 2014-09-18 |
| US9079929B2 (en) | 2015-07-14 |
| CN103987696B (zh) | 2016-12-21 |
| JP2014530240A (ja) | 2014-11-17 |
| EP2766347B1 (fr) | 2016-05-04 |
| WO2013056034A1 (fr) | 2013-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02805A (fr) | ||
| IN2014CN02806A (fr) | ||
| TN2014000155A1 (en) | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors | |
| MX2015000892A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| MX2015000919A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
| PH12014500199A1 (en) | Indazoles | |
| PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| MY201397A (en) | Primidinones as factor xia inhibitors | |
| IN2015DN00598A (fr) | ||
| IN2014MN02658A (fr) | ||
| NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
| IN2015DN01156A (fr) | ||
| MY162936A (en) | Macrocycles as factor xia inhibitors | |
| IN2014MN02657A (fr) | ||
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| UA111382C2 (uk) | Інгібітори протеїнкінази | |
| IN2014CN03803A (fr) | ||
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| GB201209587D0 (en) | Therapeutic compounds | |
| IN2014DN06869A (fr) | ||
| MX362879B (es) | Usos novedosos. |